Bimekizumab (Bimzelx)

Key Messages

• CADTH recommends that Bimzelx should be reimbursed by public drug plans for the treatment of moderate to severe plaque psoriasis if certain conditions are met.
• Bimzelx should be covered to treat adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, provided that Bimzelx is covered in a similar way to other interleukin-17 inhibitors currently reimbursed by public drug plans for the treatment of adult patients with moderate to severe plaque psoriasis.
• Bimzelx should only be reimbursed if prescribed by a dermatologist and the cost of Bimzelx is reduced.